Cargando…
Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
Autores principales: | Sharaf, Radwa, Pavlick, Dean C, Frampton, Garrett M, Cooper, Maureen, Jenkins, Jacqueline, Danziger, Natalie, Haberberger, James, Alexander, Brian M, Cloughesy, Timothy, Yong, William H, Liau, Linda M, Nghiemphu, Phioanh L, Ji, Matthew, Lai, Albert, Ramkissoon, Shakti H, Albacker, Lee A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218850/ https://www.ncbi.nlm.nih.gov/pubmed/34169283 http://dx.doi.org/10.1093/noajnl/vdab059 |
Ejemplares similares
-
FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
por: Sharaf, Radwa, et al.
Publicado: (2021) -
Clinical and analytical validation of FoundationOne(®)CDx, a comprehensive genomic profiling assay for solid tumors
por: Milbury, Coren A., et al.
Publicado: (2022) -
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors
por: Takeda, Masayuki, et al.
Publicado: (2021) -
PEDT-02 Clinical usage of NCC Oncopanel/FoundationOne CDx for pediatric/AYA patients with recurrent malignant brain tumors
por: Shibahara, Ichiyo, et al.
Publicado: (2020) -
CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1–Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion
por: Williams, Erik A., et al.
Publicado: (2020)